-

LEO Pharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST.

With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs.

Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology.

The J.P. Morgan Healthcare Conference presentation will provide investors, analysts, and partners with insights into LEO Pharma’s innovation strategy, growth momentum, and global ambitions in medical dermatology. Attendees can expect a high‑energy session that spotlights the company’s differentiated market position and outlines its next chapter of industry leadership.

Event details:

  • Westin St. Francis Hotel, San Francisco
  • Tuesday, January 13, 2026
  • 9:00 AM PST

About LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin.

For more information, visit www.leo-pharma.com.

Contacts

Investors:
Christian Boas Ryom, Investor Relations
Tel: +45 4494 5888
Email: chsoe@leo-pharma.com

Media :
Jeppe Ilkjær, Media Relations
Tel: +45 3050 2014
Email: jeilk@leo-pharma.com

LEO Pharma


Release Summary
LEO Pharma CEO Christophe Bourdon will give a company update at the J.P. Morgan Healthcare Conference in San Francisco on January 13 at 9:00 AM PST
Release Versions

Contacts

Investors:
Christian Boas Ryom, Investor Relations
Tel: +45 4494 5888
Email: chsoe@leo-pharma.com

Media :
Jeppe Ilkjær, Media Relations
Tel: +45 3050 2014
Email: jeilk@leo-pharma.com

More News From LEO Pharma

LEO Pharma Appoints Marika Murto to Lead Global Product Strategy

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma appoints Marika Murto to lead Global Product Strategy...

LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA

BALLERUP, Denmark--(BUSINESS WIRE)--NOT FOR UK USE – NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced submission of a label expansion application to the European Medicines Agency (EMA) to expand the use of Anzupgo® (delgocitinib) cream to adolescents aged 12 to 17 years, living with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate in the European Union. The label expansion application h...

LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial

BALLERUP, Denmark--(BUSINESS WIRE)--GLOBAL RELEASE - NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced positive topline key results from the 32-week analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of adult patients with atopic dermatitis with moderate-to-severe hand involvement, who are candidates for systemic therapy. ADHAND is a phase 3b, interventional, adaptive, placebo-controlled clinical trial evaluating the e...
Back to Newsroom